|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.60 DKK | +2.38% |
|
+0.14% | +1.10% |
| 06-18 | Nordea raises target price for Lundbeck to DKK60 (57), reiterates buy rating | FW |
| 06-14 | H. Lundbeck A/S Presents Preliminary Phase II Part A Data for Asedebart in Cushing's Disease | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Pharmaceuticals Wholesale
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 87.88B | |||||
| 51.94B | |||||
| 22.26B | |||||
| 7.96B | |||||
| 7.34B |
- Stock Market
- Stocks
- HLUN B Stock
- LUN Stock
- Charts Lundbeck
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
